A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Ipilimumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.